Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) PT at $43.33

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have received an average rating of "Moderate Buy" from the ten research firms that are currently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $43.33.

Several equities research analysts recently weighed in on the company. Citigroup decreased their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating for the company in a report on Wednesday, November 27th. HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, January 23rd. Piper Sandler cut their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. Chardan Capital restated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein cut their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating for the company in a research note on Friday, November 29th.

Arrowhead Pharmaceuticals Stock Performance

ARWR traded down $0.24 during trading hours on Wednesday, hitting $20.24. The stock had a trading volume of 1,415,480 shares, compared to its average volume of 2,631,224. The company's fifty day simple moving average is $20.50 and its 200 day simple moving average is $21.43. Arrowhead Pharmaceuticals has a 1 year low of $17.05 and a 1 year high of $36.72. The stock has a market cap of $2.53 billion, a PE ratio of -4.03 and a beta of 0.95. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06.

Insider Activity

In related news, Director Adeoye Y. Olukotun sold 2,850 shares of the business's stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $20.00, for a total value of $57,000.00. Following the completion of the sale, the director now owns 36,740 shares in the company, valued at $734,800. The trade was a 7.20 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director William D. Waddill sold 3,748 shares of the business's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $21.90, for a total value of $82,081.20. Following the completion of the sale, the director now owns 44,125 shares of the company's stock, valued at $966,337.50. The trade was a 7.83 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 147,432 shares of company stock worth $2,957,986. 4.30% of the stock is currently owned by insiders.

Institutional Trading of Arrowhead Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. World Investment Advisors LLC lifted its position in Arrowhead Pharmaceuticals by 3.8% in the 3rd quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company's stock worth $371,000 after buying an additional 700 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company's stock worth $88,000 after purchasing an additional 788 shares during the period. Wellington Management Group LLP increased its stake in Arrowhead Pharmaceuticals by 1.5% in the 3rd quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company's stock worth $1,199,000 after purchasing an additional 886 shares during the period. State of Alaska Department of Revenue increased its stake in Arrowhead Pharmaceuticals by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 14,417 shares of the biotechnology company's stock worth $279,000 after purchasing an additional 980 shares during the period. Finally, Van ECK Associates Corp increased its stake in Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,250 shares during the period. Institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.